Literature DB >> 22659085

Energy depletion in seizures: anaplerosis as a strategy for future therapies.

Stjepana Kovac1, Andrey Y Abramov, Matthew C Walker.   

Abstract

Seizure activity can lead to energy failure and neuronal injury, resulting in neurological and cognitive sequelae. Moreover, mutations affecting genes encoding for proteins that maintain energy homeostasis within the cell often result in an epileptic phenotype, implying that energy failure can contribute to epileptogenesis. Indeed, there is evidence to indicate that the efficacy of the ketogenic diet, a treatment for refractory epilepsy, can be partly explained by its effect on increasing energetic substrates. The ATP level, reflecting the energy level of a cell, is maintained by the potential gradient across the mitochondrial membrane. This potential gradient is maintained by NADH/H(+) equivalents, produced by reactions within the tricarboxylic acid cycle (TCA-cycle). Anaplerosis, the replenishment of TCA-cycle substrates, therefore represents an appealing strategy to address energy failure such as occurs in seizures. There is accumulating evidence that pyruvate, a classical anaplerotic substrate, has seizure suppressive effects and protects against seizure induced cell death. This review summarizes the evidence for the contribution of TCA cycle deficits in generating seizures. We highlight the role for TCA substrate supplementation in protecting against seizures and seizure induced cell death, and propose that these are important targets for future translational research addressing energy depletion in seizures. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659085     DOI: 10.1016/j.neuropharm.2012.05.012

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  25 in total

Review 1.  Mitochondrial involvement and oxidative stress in temporal lobe epilepsy.

Authors:  Shane Rowley; Manisha Patel
Journal:  Free Radic Biol Med       Date:  2013-02-11       Impact factor: 7.376

Review 2.  Ketogenic diets, mitochondria, and neurological diseases.

Authors:  Lindsey B Gano; Manisha Patel; Jong M Rho
Journal:  J Lipid Res       Date:  2014-05-20       Impact factor: 5.922

3.  Neuroprotective effects of idebenone against pilocarpine-induced seizures: modulation of antioxidant status, DNA damage and Na(+), K (+)-ATPase activity in rat hippocampus.

Authors:  Maha Ali Eissa Ahmed
Journal:  Neurochem Res       Date:  2014-01-11       Impact factor: 3.996

4.  Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.

Authors:  Juan M Pascual; Peiying Liu; Deng Mao; Dorothy I Kelly; Ana Hernandez; Min Sheng; Levi B Good; Qian Ma; Isaac Marin-Valencia; Xuchen Zhang; Jason Y Park; Linda S Hynan; Peter Stavinoha; Charles R Roe; Hanzhang Lu
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

5.  Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life.

Authors:  Julien Thevenon; Mathieu Milh; François Feillet; Judith St-Onge; Yannis Duffourd; Clara Jugé; Agathe Roubertie; Delphine Héron; Cyril Mignot; Emmanuel Raffo; Bertrand Isidor; Sandra Wahlen; Damien Sanlaville; Nathalie Villeneuve; Véronique Darmency-Stamboul; Annick Toutain; Mathilde Lefebvre; Mondher Chouchane; Frédéric Huet; Arnaud Lafon; Anne de Saint Martin; Gaetan Lesca; Salima El Chehadeh; Christel Thauvin-Robinet; Alice Masurel-Paulet; Sylvie Odent; Laurent Villard; Christophe Philippe; Laurence Faivre; Jean-Baptiste Rivière
Journal:  Am J Hum Genet       Date:  2014-07-03       Impact factor: 11.025

6.  Ketogenic and anaplerotic dietary modifications ameliorate seizure activity in Drosophila models of mitochondrial encephalomyopathy and glycolytic enzymopathy.

Authors:  Keri J Fogle; Amber R Smith; Sidney L Satterfield; Alejandra C Gutierrez; J Ian Hertzler; Caleb S McCardell; Joy H Shon; Zackery J Barile; Molly O Novak; Michael J Palladino
Journal:  Mol Genet Metab       Date:  2019-01-17       Impact factor: 4.797

7.  Altered mitochondrial acetylation profiles in a kainic acid model of temporal lobe epilepsy.

Authors:  Lindsey B Gano; Li-Ping Liang; Kristen Ryan; Cole R Michel; Joe Gomez; Athanassios Vassilopoulos; Nichole Reisdorph; Kristofer S Fritz; Manisha Patel
Journal:  Free Radic Biol Med       Date:  2018-05-17       Impact factor: 7.376

Review 8.  Glucose Transporter Type I Deficiency (G1D) at 25 (1990-2015): Presumptions, Facts, and the Lives of Persons With This Rare Disease.

Authors:  Juan M Pascual; Gabriel M Ronen
Journal:  Pediatr Neurol       Date:  2015-08-10       Impact factor: 3.372

9.  Targeting deficiencies in mitochondrial respiratory complex I and functional uncoupling exerts anti-seizure effects in a genetic model of temporal lobe epilepsy and in a model of acute temporal lobe seizures.

Authors:  Kristina A Simeone; Stephanie A Matthews; Kaeli K Samson; Timothy A Simeone
Journal:  Exp Neurol       Date:  2013-11-21       Impact factor: 5.330

Review 10.  MicroRNAs as regulators of brain function and targets for treatment of epilepsy.

Authors:  Gary P Brennan; David C Henshall
Journal:  Nat Rev Neurol       Date:  2020-06-16       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.